KODK

Eastman Kodak Company (10-K) Summary

Business Context and Reporting Period

Company: Eastman Kodak Company
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Kodak is engaged in developing, manufacturing, and marketing consumer, professional, health, and other imaging products. The company operates four primary segments: Consumer Imaging, Kodak Professional, Health Imaging, and Other Imaging. The company employs 86,200 people globally, with 46,300 in the U.S.

Key Financial Metrics (1998)

Margins: Overall gross profit margins improved to 45.6% in 1998 from 44.5% in 1997 (adjusted for promotion reclassification). SG&A expenses decreased to 24.6% of sales in 1998 from 26.9% in 1997.

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 8% year-over-year. This was largely due to the transfer of the graphics business to a joint venture (Kodak Polychrome Graphics) and unfavorable currency fluctuations ($344 million impact). Excluding these factors, sales decreased 2%.
• Earnings Recovery: Net earnings rebounded significantly from a nominal $5 million in 1997 to $1,390 million in 1998. The 1997 results were heavily impacted by a $1,455 million restructuring charge and a $186 million in-process R&D write-off (Wang acquisition).
• Segment Performance:
  • Consumer Imaging: Sales down 7% (volume declines and currency).
  • Kodak Professional: Sales down 19% (primarily due to the joint venture formation).
  • Health Imaging: Sales essentially flat; strengthened by the acquisition of Imation's medical imaging business.
  • Other Imaging: Sales down 6% due to declines in Document Imaging and Commercial & Government Systems.
• Cost Reductions: The company achieved approximately $730 million in operating cost savings in 1998 through restructuring programs initiated in 1996 and 1997.

Guidance, Outlook, Risks, and Unusual Items

Unusual Items & Charges (1998):

• Office Imaging Charge: A pre-tax charge of $132 million ($87 million after-tax) due to asset write-downs and severance resulting from volume reductions by primary customer Danka Business Systems PLC.
• Imation Acquisition Charge: A pre-tax charge of $45 million ($30 million after-tax) for in-process R&D associated with the acquisition of Imation Corp.'s medical imaging business.
• Gains on Sales: Pre-tax gains of $87 million (NanoSystems sale) and $66 million (partial sale of Gretag Imaging Group investment).

Outlook & Strategy:

• Cost Reduction Target: Management increased the minimum target for cost reductions to $1.2 billion by the end of 1999.
• China Investment: Plans to invest more than $1 billion in China over the next several years to upgrade technology and expand distribution.
• Digital Transition: Continued investment in digital imaging products and partnerships (e.g., Intel, AOL) to bridge traditional and digital markets.

Risks & Contingencies:

• Year 2000 Compliance: Estimated remediation costs of $12 million for 1999 and $6 million for 2000. Risks include potential system failures and third-party supplier non-compliance.
• Legal Proceedings: Successful mediation concluded major antitrust litigation (ITS, Nationwide, A-1) with payments covered by existing reserves. A proposed administrative Consent Order from the NY State Department of Environmental Conservation is pending, with an expected civil penalty in excess of $100,000.
• Office Imaging Uncertainty: The company continues to assess strategic options for its Office Imaging business following the termination of agreements with Danka, which could materially impact 1999 results.

Investor Verification Checklist

• Danka Dependency: Verify the status of the Office Imaging business and the extent of remaining exposure to Danka Business Systems PLC.
• Restructuring Savings: Confirm the realization of the $1.2 billion cost reduction target by end of 1999 and the sustainability of these savings.
• China Investments: Monitor the execution and ROI of the planned $1 billion+ investment in Chinese operations.
• Year 2000 Readiness: Assess the progress of mission-critical IT and manufacturing system compliance to mitigate operational disruption risks.
• Environmental Liabilities: Review the final settlement terms of the NY State environmental consent order and ongoing Superfund obligations.